Physician profile
Brian Michael Starr
NPI 1104086859
$3,309.70
in general payments reported to CMS, 2019-2025
20 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $633 · 2023: $562 · 2024: $1,009 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,090.76 | 2021-2024 | Proclaim, Ionicrf |
| Medtronic, INC. | $704.88 | 2024-2025 | Kyphon Express II Kyphopak Tray, Inceptiv, Catalyft Pl Expandable Interbody System |
| Boston Scientific Corporation | $413.34 | 2024-2025 | General - Pain Management, Intracept |
| Amgen INC. | $288.47 | 2023-2024 | Tavneos, Otezla |
| Si-Bone, INC. | $161.32 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.42 | 2024 | |
| Abbvie INC. | $97.05 | 2021-2023 | Ubrelvy |
| Relievant Medsystems, INC. | $94.98 | 2022-2023 | Intracept |
| Averitas Pharma INC. | $43.33 | 2023-2024 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $42.83 | 2024 | Ajovy |
| Grt US Holding, INC. | $41.76 | 2022 | |
| Ibsa Pharma INC. | $36.92 | 2021-2022 | |
| Painteq LLC | $29.82 | 2023 | Painteq |
| Collegium Pharmaceutical, INC. | $29.51 | 2023-2024 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $26.59 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $24.76 | 2022 | |
| Nevro Corp. | $23.10 | 2024 | Senza |
| Fidia Pharma USA INC. | $20.38 | 2023 | Hymovis, Triluron |
| Pfizer INC. | $14.41 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.